Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

pediatrics

- PMLiVE

Pfizer’s RSV vaccine approved by FDA for older adults

RSV infections in older adults account for up to 160,000 hospitalisations each year in the US

- PMLiVE

COVID-19: Pfizer’s Paxlovid approved by FDA and Gilead’s Veklury recommended by CHMP

Pfizer’s oral antiviral was granted accelerated approval in the US in December 2021

- PMLiVE

Pfizer’s maternal RSV vaccine candidate backed by FDA advisory committee

Up to 80,000 children aged under five are hospitalised each year in the US due to RSV infection

- PMLiVE

Roche reports positive results for drug for relapsing forms of MS

The neurological disease affects approximately 2.8 million people worldwide

- PMLiVE

Astellas Pharma’s non-hormonal menopause drug granted FDA approval

Vasomotor symptoms affect up to 80% of menopausal individuals in the US

- PMLiVE

Pfizer’s next-generation pneumococcal vaccine granted FDA approval

The vaccine can help protect against 20 serotypes of the streptococcus pneumoniae bacteria

Biogen Idec building

Biogen’s Qalsody granted FDA accelerated approval for rare form of ALS

Mutations in the SOD1 gene are responsible for approximately 2% of all cases

- PMLiVE

Authorisation for Moderna and Pfizer/BioNTech’s bivalent COVID-19 vaccines simplified by FDA

The vaccines are now authorised for all doses in individuals aged six months and older

- PMLiVE

Roche reports positive phase 3 data for Tecentriq combination in liver cancer

More than 900,000 people are diagnosed with the disease globally each year

The ongoing evolution of Medical Affairs

In the latest episode of Impetus Digital's Fireside Chat series, Natalie Yeadon, Co-Founder and CEO of Impetus Digital talks to Eddie Power, Vice President of North America Medical Affairs, Hospital...

Impetus Digital

Biogen Idec building

Biogen and Eisai’s Alzheimer’s drug associated with positive long-term health outcomes

A simulation model estimated lecanemab to potentially slow the rate of disease progression

- PMLiVE

Cytokinetics to discontinue ALS drug candidate following phase 3 trial failure

The neurodegenerative disease affects approximately 27,000 people in the US

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links